Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

BACKGROUND: The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been approved for the treatment of metastatic CRC, however tumor response to cetuximab has not been found to be associated with EGF...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Razis, Evangelia, Briasoulis, Evangelos, Vrettou, Eleni, Skarlos, Dimosthenis V, Papamichael, Dimitrios, Kostopoulos, Ioannis, Samantas, Epaminontas, Xanthakis, Ioannis, Bobos, Mattheos, Galanidi, Eleni, Bai, Maria, Gikonti, Ioanna, Koukouma, Alona, Kafiri, Georgia, Papakostas, Pavlos, Kalogeras, Konstantine T, Kosmidis, Paris, Fountzilas, George
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2008
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2527615/
https://ncbi.nlm.nih.gov/pubmed/18700047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-234
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars